Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference85 articles.
1. Global cancer statistics 2002;Parkin;CA Cancer J Clin,2005
2. Lung cancer: district active treatment rates affect survival;Cartman;J Epidemiol Community Health,2002
3. Prospective population-based study on the survival of patients with lung cancer;Makitaro;Eur Respir J,2002
4. Non-small cell lung cancer;Ginsberg,2001
5. The concurrent chemoradiation paradigm-general principles;Seiwert;Nat Clin Pract Oncol,2007
Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Metabolism and pharmacokinetic study of deuterated osimertinib;Biopharmaceutics & Drug Disposition;2023-02-03
2. EFFECT OF ERLOTINIB COMBINED WITH BEVACIZUMAB ON IMMUNE RESPONSE AND SERUM TUMOR MARKERS IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER;ACTA MEDICA MEDITERR;2023
3. Mechanism of glycitein in the treatment of colon cancer based on network pharmacology and molecular docking;Lifestyle Genomics;2022-09-30
4. Effect of Astragalus Polysaccharide on the Expression of VEGF and EGFR in Mice with Lewis Transplantable Lung Cancer;Journal of the College of Physicians and Surgeons Pakistan;2019-04-01
5. Radical and Incremental Innovation Problem-Driven to Support Competitive Advantage of Firms;SSRN Electronic Journal;2017
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3